[DOI] [PMC free article] [PubMed] [Google Scholar] 99
Two pharmacies might compound semaglutide at the same concentration using similar formulation approaches and assign wildly different BUDs, one at 28 days and another at 90 days, simply because one invested in more comprehensive stability testing
Since then, 17 additional medications have been approved by the FDA, but many have been withdrawn because of adverse effects, several are only approved for short-term (less than 12 weeks) use, and only 5 are currently available for long-term obesity therapy in the US
swelling of the hands, feet, ankles, face, lips and mouth or throat, which may cause difficulty in swallowing or breathing
Moon MJ, Lee YN, Park S, Reyes-Alcaraz A, Hwang JI, Millar RP, et al
NICE guidance emphasises the importance of patient-centred care and shared decision-making in obesity management